4.79
price down icon1.24%   -0.06
after-market Handel nachbörslich: 4.76 -0.03 -0.63%
loading
Schlusskurs vom Vortag:
$4.85
Offen:
$4.8
24-Stunden-Volumen:
587.35K
Relative Volume:
1.04
Marktkapitalisierung:
$279.21M
Einnahmen:
$192.64M
Nettoeinkommen (Verlust:
$2.51M
KGV:
17.74
EPS:
0.27
Netto-Cashflow:
$12.42M
1W Leistung:
+2.13%
1M Leistung:
+3.46%
6M Leistung:
-1.84%
1J Leistung:
+5.97%
1-Tages-Spanne:
Value
$4.66
$4.80
1-Wochen-Bereich:
Value
$4.56
$4.885
52-Wochen-Spanne:
Value
$3.295
$6.75

Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile

Name
Firmenname
Vanda Pharmaceuticals Inc
Name
Telefon
202-734-3400
Name
Adresse
2200 PENNSYLVANIA AVE NW, WASHINGTON
Name
Mitarbeiter
203
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
VNDA's Discussions on Twitter

Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-07-11 Eingeleitet Cantor Fitzgerald Overweight
2022-02-25 Herabstufung Jefferies Buy → Hold
2021-05-12 Eingeleitet BofA Securities Buy
2021-01-14 Herabstufung Citigroup Buy → Neutral
2020-10-29 Hochstufung Citigroup Neutral → Buy
2020-06-09 Herabstufung Citigroup Buy → Neutral
2020-03-16 Herabstufung Oppenheimer Perform → Underperform
2020-03-12 Hochstufung Citigroup Neutral → Buy
2019-11-07 Herabstufung Citigroup Buy → Neutral
2019-08-01 Hochstufung Citigroup Neutral → Buy
2019-07-25 Herabstufung Stifel Buy → Hold
2018-12-11 Herabstufung Oppenheimer Outperform → Perform
2018-12-04 Hochstufung Cantor Fitzgerald Neutral → Overweight
2018-12-04 Bestätigt Jefferies Buy
2018-11-08 Fortgesetzt Jefferies Buy
2018-09-21 Fortgesetzt Oppenheimer Outperform
2018-05-23 Eingeleitet Citigroup Buy
2018-01-19 Eingeleitet Seaport Global Securities Buy
2017-09-14 Bestätigt Piper Jaffray Overweight
2017-06-27 Fortgesetzt Piper Jaffray Overweight
2017-05-26 Eingeleitet H.C. Wainwright Buy
2017-04-12 Eingeleitet Oppenheimer Outperform
2016-11-09 Eingeleitet Aegis Capital Buy
2016-10-06 Fortgesetzt Jefferies Buy
Alle ansehen

Vanda Pharmaceuticals Inc Aktie (VNDA) Neueste Nachrichten

pulisher
02:19 AM

Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve

02:19 AM
pulisher
08:20 AM

Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks - Simply Wall St

08:20 AM
pulisher
Nov 04, 2024

Brokers Set Expectations for VNDA Q3 Earnings - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

Vanda started at buy by H.C. Wainwright, negative enterprise value cited - MSN

Nov 02, 2024
pulisher
Nov 01, 2024

Over 200% Stock UpsideVanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Brokers Issue Forecasts for VNDA FY2024 Earnings - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

StockNews.com Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

Vanda Pharmaceuticals (VNDA) Set to Announce Quarterly Earnings on Wednesday - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Buy Rating from Analysts at HC Wainwright - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

VNDAVanda Pharmaceuticals Inc. Latest Stock News & Market Updates - StockTitan

Oct 31, 2024
pulisher
Oct 30, 2024

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024 - StockTitan

Oct 30, 2024
pulisher
Oct 28, 2024

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Sees Significant Growth in Short Interest - MarketBeat

Oct 28, 2024
pulisher
Oct 24, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated at StockNews.com - MarketBeat

Oct 24, 2024
pulisher
Oct 22, 2024

Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More - MSN

Oct 22, 2024
pulisher
Oct 21, 2024

Allergic Conjunctivitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO - The Globe and Mail

Oct 21, 2024
pulisher
Oct 19, 2024

Vanda Pharma soars as Cycle Pharma reiterates $8/share offer (update) - MSN

Oct 19, 2024
pulisher
Oct 17, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc.VNDA - PR Newswire

Oct 17, 2024
pulisher
Oct 16, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises - Yahoo Finance

Oct 15, 2024
pulisher
Oct 15, 2024

Cycle Pharmaceuticals reaffirms proposal to acquire Vanda Pharmaceuticals - Yahoo Finance

Oct 15, 2024
pulisher
Oct 15, 2024

D.C. drugmaker Vanda rejects another acquisition offer - The Business Journals

Oct 15, 2024
pulisher
Oct 15, 2024

Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share - BioSpace

Oct 15, 2024
pulisher
Oct 15, 2024

Cycle Pharmaceuticals Makes Bold Move To Acquire Vanda Pharma - Finimize

Oct 15, 2024
pulisher
Oct 14, 2024

Vanda Pharmaceuticals rejects Cycle Pharma's second takeover offer - Reuters

Oct 14, 2024
pulisher
Oct 14, 2024

Vanda Pharmaceuticals Rejects Deal Proposal From Cycle Group - MarketWatch

Oct 14, 2024
pulisher
Oct 14, 2024

Cycle Pharmaceuticals Stands By $488 Million Offer for Vanda - Yahoo Finance

Oct 14, 2024
pulisher
Oct 14, 2024

Vanda Pharmaceuticals rejects Cycle Group's $8.00 per share bid - Investing.com

Oct 14, 2024
pulisher
Oct 14, 2024

Cycle Pharma maintains takeover offer for Vanda Pharmaceuticals - WHBL

Oct 14, 2024
pulisher
Oct 14, 2024

Vanda Pharmaceuticals rejects Cycle Group's $8.00 per share bid By Investing.com - Investing.com UK

Oct 14, 2024
pulisher
Oct 14, 2024

Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd. - PR Newswire

Oct 14, 2024
pulisher
Oct 14, 2024

Vanda Pharma stock soars as Cycle Pharma reiterates $8/share offer - Seeking Alpha

Oct 14, 2024
pulisher
Oct 14, 2024

Cycle Pharmaceuticals offers $8 per share for Vanda By Investing.com - Investing.com UK

Oct 14, 2024
pulisher
Oct 14, 2024

Cycle Pharma Is Said to Stand By $488 Million Offer for Vanda - AllSides

Oct 14, 2024
pulisher
Oct 13, 2024

Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA for approximately $490 million. - Marketscreener.com

Oct 13, 2024
pulisher
Oct 11, 2024

Profit Investment Management LLC Lowers Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat

Oct 11, 2024
pulisher
Oct 10, 2024

Squarepoint Ops LLC Decreases Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat

Oct 10, 2024
pulisher
Oct 09, 2024

Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies | DelveInsight - GlobeNewswire Inc.

Oct 09, 2024
pulisher
Oct 07, 2024

US Supreme Court reportedly declines to hear Vanda patent case - MSN

Oct 07, 2024
pulisher
Oct 07, 2024

Dimensional Fund Advisors LP Purchases 292,172 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat

Oct 07, 2024
pulisher
Oct 05, 2024

Sei Investments Co. Sells 123,694 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat

Oct 05, 2024
pulisher
Oct 04, 2024

Vanda Pharmaceuticals updates bylaws, clarifies stockholder meetings By Investing.com - Investing.com Canada

Oct 04, 2024
pulisher
Oct 03, 2024

Vanda Pharmaceuticals updates bylaws, clarifies stockholder meetings - Investing.com India

Oct 03, 2024

Finanzdaten der Vanda Pharmaceuticals Inc-Aktie (VNDA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Kapitalisierung:     |  Volumen (24h):